Bausch Health Cos Inc. (NYSE:BHC – Free Report) – Analysts at Zacks Research upped their FY2026 EPS estimates for Bausch Health Cos in a research report issued on Wednesday, August 19th. Zacks Research analyst Team now forecasts that the company will earn $4.24 per share for the year, up from their previous forecast of $3.93. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.24 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q4 2026 earnings at $1.16 EPS.
BHC has been the subject of several other reports. Royal Bank Of Canada cut their price objective on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a report on Monday, April 27th. Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings raised Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $8.00.
Bausch Health Cos Stock Performance
Shares of BHC stock opened at $6.88 on Thursday. The stock has a market capitalization of $2.57 billion, a P/E ratio of -2.32 and a beta of 0.38. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. The firm’s 50 day moving average is $5.30 and its 200 day moving average is $5.45. Bausch Health Cos has a 12 month low of $4.33 and a 12 month high of $8.00.
Bausch Health Cos (NYSE:BHC – Get Free Report) last posted its earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.30. The firm had revenue of $2.83 billion during the quarter, compared to the consensus estimate of $2.59 billion. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%.
Hedge Funds Weigh In On Bausch Health Cos
Large investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio purchased a new position in Bausch Health Cos during the second quarter valued at approximately $2,565,000. Bank of America Corp DE purchased a new stake in Bausch Health Cos in the 2nd quarter worth approximately $2,816,000. Paulson & CO. Inc. purchased a new stake in Bausch Health Cos in the 2nd quarter worth approximately $361,151,000. Man Group plc bought a new position in Bausch Health Cos in the 2nd quarter valued at $7,157,000. Finally, Biglari Capital CORP. bought a new position in Bausch Health Cos in the 2nd quarter valued at $202,475,000. 78.65% of the stock is currently owned by institutional investors.
About Bausch Health Cos
Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.
The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.
See Also
- Five stocks we like better than Bausch Health Cos
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Bausch Health Cos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Cos and related companies with MarketBeat.com's FREE daily email newsletter.
